Cargando…
YM155-Adapted Cancer Cell Lines Reveal Drug-Induced Heterogeneity and Enable the Identification of Biomarker Candidates for the Acquired Resistance Setting
Survivin is a drug target and its suppressant YM155 a drug candidate mainly investigated for high-risk neuroblastoma. Findings from one YM155-adapted subline of the neuroblastoma cell line UKF-NB-3 had suggested that increased ABCB1 (mediates YM155 efflux) levels, decreased SLC35F2 (mediates YM155 u...
Autores principales: | Michaelis, Martin, Wass, Mark N., Reddin, Ian, Voges, Yvonne, Rothweiler, Florian, Hehlgans, Stephanie, Cinatl, Jaroslav, Mernberger, Marco, Nist, Andrea, Stiewe, Thorsten, Rödel, Franz, Cinatl, Jindrich |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281096/ https://www.ncbi.nlm.nih.gov/pubmed/32357518 http://dx.doi.org/10.3390/cancers12051080 |
Ejemplares similares
-
Effects of YM155 on survivin levels and viability in neuroblastoma cells with acquired drug resistance
por: Voges, Yvonne, et al.
Publicado: (2016) -
Testing of the Survivin Suppressant YM155 in a Large Panel of Drug-Resistant Neuroblastoma Cell Lines
por: Michaelis, Martin, et al.
Publicado: (2020) -
ABCB1 as predominant resistance mechanism in cells with acquired SNS-032 resistance
por: Löschmann, Nadine, et al.
Publicado: (2016) -
Drug-adapted cancer cell lines as preclinical models of acquired resistance
por: Michaelis, Martin, et al.
Publicado: (2019) -
ABCG2 impairs the activity of the aurora kinase inhibitor tozasertib but not of alisertib
por: Michaelis, Martin, et al.
Publicado: (2015)